Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aevi Genomic Medicine Inc (NASDAQ:GNMX)

4.62
Delayed Data
As of Feb 24
 -0.09 / -1.91%
Today’s Change
3.60
Today|||52-Week Range
6.89
-10.81%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$171.4M

Company Description

Aevi Genomic Medicine, Inc. is a medical technology company, which focuses on finding treatments for rare and orphan diseases, with a particular focus on pediatrics, following a genomics medicine strategy. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

Contact Information

Aevi Genomic Medicine, Inc.
435 Devon Park Drive
Wayne Pennsylvania 19087
P:(610) 254-4201
Investor Relations:

Employees

Shareholders

Other institutional32.51%
Mutual fund holders13.42%
Individual stakeholders0.38%

Top Executives

Michael F. ColaPresident, Chief Executive Officer & Director
Brian D. PiperCFO, Principal Financial & Accounting Officer
Garry Arthur NeilChief Scientific Officer